Neo-adjuvant Pembrolizumab in Primary Stage IV Ovarian Cancer
Status:
Recruiting
Trial end date:
2025-06-01
Target enrollment:
Participant gender:
Summary
This is a single arm feasibility study in patients with primary FIGO stage IV serous ovarian,
peritoneal, or fallopian tube cancer to evaluate neo-adjuvant + adjuvant pembrolizumab for
its capacity to induce and broaden T cell responses against tumor neo-antigens.